Common questions about Gliclazida Azevedos (FAQ)
Q: How quickly should Gliclazida Azevedos start showing an effect?
A: Official product information notes that the medicine’s concentration in the bloodstream typically reaches its maximum level, or a plateau, between 6 and 12 hours after taking the modified-release tablet. The medicine works by stimulating the release of insulin, and official documents describe that a significant increase in this release occurs following stimulation from a meal or glucose.
Q: Is it necessary to monitor blood sugar closely when on Gliclazida Azevedos?
A: Monitoring of blood glucose is an important regulatory requirement during treatment. This is particularly emphasized in regulatory documents during initial dose adjustments or when taking the medication alongside other medicines that can affect blood sugar levels, as a precautionary measure against the risk of low blood sugar.
Q: What type of monitoring is required while taking Gliclazida Azevedos?
A: Regulatory information advises the patient to be involved in monitoring their own blood glucose levels. To assess the medicine's overall effectiveness, key biomarkers are tracked, including Glycated Hemoglobin (HbA1c), which reflects long-term control, and both fasting and after-meal plasma glucose levels.
Q: Does Gliclazida Azevedos cause tiredness or dizziness?
A: The official safety profile describes low blood sugar (hypoglycemia) as the most common adverse reaction documented. Regulatory patient information states that dizziness and unusual tiredness are possible signs of low blood sugar.
Q: What happens if Gliclazida Azevedos is taken with herbal supplements?
A: Regulatory patient information specifically advises against taking the herbal remedy St John’s wort, as it may change how your body processes the medicine. For most other herbal remedies and supplements, official guidance states there is not enough data to confirm safety regarding interactions with Gliclazide.
Q: What happens if Gliclazida Azevedos stops working for me?
A: If a loss of control of blood glucose (hyperglycemia, or high blood sugar) occurs, regulatory guidelines indicate that dosage adjustment or alternative therapy may be necessary. This approach is consistent with established therapeutic protocols.
Q: Can I stop taking Gliclazida Azevedos once my blood sugar levels improve?
A: Gliclazide is intended for the long-term control of high blood sugar in Type 2 diabetes and is not a cure. Regulatory patient information advises continuing the medicine for the duration recommended by the prescribing physician to maintain glucose management.
Q: Is it important to take Gliclazida Azevedos at the exact same time every day?
A: Regulatory patient information for the modified-release formulation indicates that taking the tablet at the same time each day, typically with breakfast, is important. This adherence helps to ensure a consistent release and effect of the medication throughout the day.
Q: Is Gliclazida Azevedos the same kind of medicine as metformin?
A: Gliclazide belongs to the sulfonylurea derivative class of drugs. Metformin belongs to the biguanide class of drugs. Official information confirms these are different pharmacological classes with distinct mechanisms of action used for blood glucose control.
Q: What is the main difference between Gliclazida and Gliclazida Azevedos?
A: Gliclazide is the official active ingredient that lowers blood sugar. Gliclazida Azevedos is a specific brand name under which the medicine containing Gliclazide is sold and marketed.
Q: Can Gliclazida Azevedos affect my weight?
A: Regulatory patient information notes that some individuals experience weight gain while taking this medication. This is a potential observed side effect, but individual experience may vary.
Q: Do I need to change my diet when taking Gliclazida Azevedos?
A: Regulatory documents describe the medicine's use as being supported by dietary management. Official warnings highlight that factors such as dietary changes or an imbalance in food intake increase the risk of low blood sugar (hypoglycemia).
Q: Are there any common foods or drinks that interact with Gliclazida Azevedos?
A: Regulatory documents list alcohol as a non-recommended combination due to interaction. No specific common foods are listed as medicinal product interactions; however, regulatory warnings note that irregular mealtimes or skipping meals increase the risk of low blood sugar (hypoglycemia).
Q: Is it normal to feel shaky or hungry after taking Gliclazida Azevedos?
A: Regulatory patient information describes feeling shaky or anxious and feeling hungry as classic, recognizable signs of low blood sugar (hypoglycemia), which is the most common adverse reaction documented.
Q: Are there special considerations for older adults taking Gliclazida Azevedos?
A: Use in older patients often begins at the minimum labeled dose. Pharmacokinetic studies show that the medicine’s clearance is slightly reduced with age, but official regulatory documents generally do not consider this reduction to be clinically significant.
Q: Is there a link between Gliclazida Azevedos and liver issues?
A: The safety profile includes the risk of Hepatobiliary Disorders, which involves the liver and bile system. This may involve elevated liver enzyme levels or, rarely, a serious condition called cholestatic jaundice, which regulatory documents describe as requiring the discontinuation of treatment.
Q: How does Gliclazida Azevedos compare to other sulfonylureas?
A: Gliclazide is classified as a second-generation sulfonylurea. Official literature describes it as being differentiated from certain older members of the class due to reported antioxidant properties and generally being associated with a low risk of hypoglycemia.
Q: Does Gliclazida Azevedos have a generic equivalent?
A: The active ingredient in the medicine is Gliclazide. It is available under various brand names in addition to Gliclazida Azevedos, which is typical for a drug with a generic equivalent.
Q: What is the risk of low blood sugar (hypoglycemia) with Gliclazida Azevedos?
A: Hypoglycemia (low blood sugar) is documented as a Common adverse reaction. In clinical studies, the modified-release formulation has been reported to occur in approximately 5% of patients.
Q: What is the purpose of the 'Azevedos' part of the name?
A: The term 'Azevedos' is part of the specific trade or brand name under which the medicine is sold. It is used to distinguish the product from other formulations or brands that contain the same active ingredient, Gliclazide.
Q: Can Gliclazida Azevedos cause changes in appetite?
A: Patient materials indicate that increased hunger is listed as a classic symptom of low blood sugar (hypoglycemia), the most common adverse reaction documented for this medicine.
Q: Are there any mental health side effects reported for Gliclazida Azevedos?
A: Patient information notes that symptoms of low blood sugar (hypoglycemia), the most common adverse reaction, may include feeling anxious or symptoms similar to a change in behavior. These symptoms are related to the acute physiological effects of low glucose.
Q: Are there differences between the different strengths of Gliclazida Azevedos tablets?
A: The different strengths (e.g., 30 mg vs. 60 mg) contain different amounts of the active ingredient and are used to achieve the dose prescribed by a physician. The modified-release formulation is designed to be taken once daily regardless of the strength needed.
Q: Does Gliclazida Azevedos affect blood clotting or bruising?
A: Official documentation notes that Gliclazide has been shown to have effects on the blood, including a partial inhibition of platelet aggregation. These actions are independent of blood glucose lowering and are documented as not being accompanied by clinical abnormalities of blood clotting.
Q: What is the half-life of Gliclazida Azevedos?
A: The elimination half-life for Gliclazide is documented to be approximately 16 hours. The half-life refers to the time it takes for the concentration of the medicine in the blood to reduce by half.
Q: What if I need surgery? Should I stop Gliclazida Azevedos?
A: Regulatory-aligned guidance describes that the medicine is generally omitted on the day of surgery (e.g., the morning dose for morning surgery) to minimize the risk of low blood sugar. Alternative therapy is typically used during this perioperative period.
Q: Do studies suggest Gliclazida Azevedos has any benefits beyond lowering blood sugar?
A: Official literature notes that Gliclazide has demonstrated certain extra-pancreatic and haemovascular properties. These include anti-oxidant effects and a partial inhibition of platelet aggregation that are separate from its primary blood glucose-lowering action.
Q: How is Gliclazida Azevedos typically described in official documents regarding its use?
A: Official documents describe the medicine as an oral antidiabetic agent of the sulfonylurea derivative class. It is consistently indicated for the treatment of Type 2 Diabetes Mellitus to achieve systemic blood glucose lowering.
Q: Why is Gliclazida Azevedos sometimes prescribed with other diabetes drugs?
A: Gliclazide may be combined with other diabetes drugs when a single medication is not sufficient to achieve adequate blood sugar control. Clinical studies show that combination therapy may lead to a more effective reduction in the HbA1c biomarker, indicating better overall control.
Q: Is Gliclazida Azevedos considered a long-term treatment?
A: The medicine is intended for the long-term control of high blood sugar in Type 2 diabetes. It is meant to be continued as recommended by the prescribing physician, as it helps manage the condition but does not provide a cure.
Q: What research evidence supports the use of Gliclazida Azevedos?
A: The research evidence is primarily based on Randomized Controlled Trials and long-term observational studies, which have examined the medicine’s effect on key biomarkers like Glycated Hemoglobin (HbA1c) and fasting plasma glucose in adults with Type 2 Diabetes Mellitus.
Q: What is the 'How it works' description for Gliclazida Azevedos in simple terms?
A: In simple terms, Gliclazide works mainly by stimulating the pancreas to release more insulin. This increased insulin is then able to help regulate blood glucose, which is the medication’s fundamental utility for managing high blood sugar.
